Современные критерии оценки лечебного патоморфоза синовиальной саркомы: клиническое значение и прогнозирование исходов

Синовиальная саркома представляет собой редкую злокачественную опухоль мягких тканей, характеризующуюся высокой агрессивностью и склонностью к метастазированию. Оценка лечебного патоморфоза играет ключевую роль в прогнозировании исходов заболевания и выборе оптимальной тактики терапии. В данной статье рассматриваются морфологические и молекулярные особенности синовиальной саркомы, существующие классификации патоморфоза, современные методы его оценки, а также прогностическая значимость степени патоморфоза. Особое внимание уделяется влиянию различных факторов на эффективность терапии, перспективам персонализированной медицины и внедрению инновационных технологий в диагностику и лечение данной опухоли.

1. Gazendam A.M., Popovic S., Munir S. et al. Synovial sarcoma: a clinical review. Curr Oncol 2021;28(3):177. DOI: 10.3390/curroncol28030177

2. Lesovaya E.A., Fetisov T.I., Bokhyan B.Y. et al. Genetic and molecular heterogeneity of synovial sarcoma and associated challenges in therapy. Cells 2024;13(20):1695. DOI: 10.3390/cells13201695

3. Qiu H., Tang Z., Nie D. Primary renal synovial sarcomas diagnosed by a novel fusion gene. Oncologie 2024;26(1):679–85. DOI: 10.1515/oncologie-2024-0101

4. Landuzzi L., Manara M.C., Pazzaglia L. et al. Innovative breakthroughs for the treatment of advanced and metastatic synovial sarcoma. Cancers (Basel) 2023;15(15):3887. DOI: 10.3390/cancers15153887

5. Righi A., Gambarotti M., Benini S. et al. Primary synovial sarcoma of bone: a retrospective analysis of 25 patients. Histopathology 2022; 81(6):912–21. DOI: 10.1111/his.14602

6. Tay T.K.Y., Sukma N.B., Lim T.H. et al. Correlating SS18-SSX immunohistochemistry with SS18 FISH in synovial sarcomas. Virchows Arch 2021;479(4):785–93. DOI: 10.1007/s00428-021-03135-0

7. Fiore M., Sambri A., Spinnato P. et al. The biology of synovial sarcoma: state-of-the-art and future perspectives. Curr Treat Options Oncol 2021;22(12):109. DOI: 10.1007/s11864-021-00914-4

8. Murphey M.D., Gibson M.S., Jennings B.T. et al. From the archives of the AFIP: Imaging of synovial sarcoma with radiologic-pathologic correlation. Radiographics 2006;26(5):1543–65. DOI: 10.1148/rg.265065084

9. Kadam S.S., Kadam T. Primary gastric synovial sarcoma in a young male: a rare case report and review of literature. Indian J Surg Oncol 2023;14(3):690–3. DOI: 10.1007/s13193-023-01738-4

10. Folpe A.L., Schmidt R.A., Chapman D., Gown A.M. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high-grade malignant peripheral nerve sheath tumors. Am J Surg Pathol 1998;22(6):673–82. DOI: 10.1097/00000478-199806000-00004

11. Baranov E., McBride M.J., Bellizzi A.M. et al. A novel SS18-SSX fusion-specific antibody for the diagnosis of synovial sarcoma. Am J Surg Pathol 2020;44(7):922–33. DOI: 10.1097/PAS.0000000000001447

12. Henderson D.W., Reid G., Kao S.C. et al. Challenges and controversies in the diagnosis of malignant mesothelioma: part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, and other tumors. J Clin Pathol 2013;66(10):818–23. DOI: 10.1136/jclinpath-2013-201609

13. Thoenen E., Curl A., Iwakuma T. TP53 in bone and soft tissue sarcomas. Pharmacol Ther 2019;202:149–64. DOI: 10.1016/j.pharmthera.2019.06.010

14. Hirakawa N., Naka T., Yamamoto I. et al. Overexpression of bcl-2 protein in synovial sarcoma: a comparative study of other soft tissue spindle cell sarcomas and an additional analysis by fluorescence in situ hybridization. Hum Pathol 1996;27(10):1060–5. DOI: 10.1016/s0046-8177(96)90284-1

15. Feng Q., Guo P., Wang J. et al. High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas. Exp Ther Med 2018;15(3):2597–603. DOI: 10.3892/etm.2018.5684

16. El Beaino M., Jupiter D.C., Assi T. et al. Diagnostic value of TLE1 in synovial sarcoma: a systematic review and meta-analysis. Sarcoma 2020;2020:7192347. DOI: 10.1155/2020/7192347

17. Thway K., Fisher C. Synovial sarcoma: defining features and diagnostic evolution. Ann Diagn Pathol 2014;18(6):369–80. DOI: 10.1016/j.anndiagpath.2014.09.002

18. Machen S.C., Gautam P., Tubbs R.R., Goldblum J.R. Utility of cytokeratin subsets for distinguishing poorly differentiated synovial sarcoma from peripheral primitive neuroectodermal tumour. Histopathology 1998;33(6):501–7. DOI: 10.1046/j.1365-2559.1998.00562.x

19. Nassif E.F., Auclin E., Bahleda R. et al. TP53 Mutation as a prognostic and predictive marker in sarcoma: pooled analysis of MOSCATO and ProfiLER precision medicine trials. Cancers 2021;13(13):3362. DOI: 10.3390/cancers13133362

20. Mancarella C., Morrione A., Scotlandi K. Unraveling the IGF system interactome in sarcomas exploits novel therapeutic options. Cells 2021;10(8):2075. DOI: 10.3390/cells10082075

21. Krasny L., Arthur A., Guljar N. et al. Characterisation of a novel cell line (ICR-SS-1) established from a patient-derived xenograft of synovial sarcoma. Cells 2022;11(15):2418. DOI: 10.3390/cells11152418

22. Roy P., Biswal R., Honap S.N., Thambudorai R. et al. A re-look at the modified Ryan regression scoring system in esophageal cancer — validation of prognostic significance and comparison with other less commonly used systems. Indian J Pathol Microbiol 2024;67(4):758–65. DOI: 10.4103/ijpm.ijpm_109_23

23. Drago S.G., Maino C., Giandola T.P. et al. Correlations between apparent diffusion coefficient (ADC) and prognosis in patients with locally advanced rectal cancer. Life 2024;14(10):1282. DOI: 10.3390/life14101282

24. Киселев Н.М., Климин С.А., Колесник Я.И. и др. Периоперационная химиотерапия и морфологический ответ в лечении рака желудка. Современная онкология 2024;26(3):276–83. DOI: 10.26442/18151434.2024.3.202978

25. Öner İ., Türkel A., İnci B.K. et al. Impact of the CPS-EG score as a new prognostic biomarker in triple-negative breast cancer patients who received neoadjuvant chemotherapy. BMC Cancer 2024;24:420. DOI: 10.1186/s12885-024-13100-0

26. Callegaro D., Miceli R., Mariani L et al. Soft tissue sarcoma nomograms and their incorporation into practice. Cancer 2017;123(17):2802–20. DOI: 10.1002/cncr.30721

27. Pillozzi S., Bernini A., Palchetti I. et al. Soft tissue sarcoma: an insight on biomarkers at molecular, metabolic and cellular level. Cancers 2021;13(12):3044. DOI: 10.3390/cancers13123044

28. Jerby-Arnon L., Neftel C., Shore M.E. et al. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med 2021;27(6):845–56. DOI: 10.1038/s41591-020-01212-6

29. Peeken J.C., Asadpour R., Specht K. et al. MRI-based delta-radiomics predicts pathologic complete response in high-grade soft-tissue sarcoma patients treated with neoadjuvant therapy. Radiother Oncol 2021;164:73–82. DOI: 10.1016/j.radonc.2021.08.023

30. Trassard M., Le Doussal V., Hacène K. et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001;19(2):525–34. DOI: 10.1200/JCO.2001.19.2.525

31. Igarashi K., Kawaguchi K., Li S. et al. Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget 2018;9(27):19263–72. DOI: 10.18632/oncotarget.24996

32. Li X., Hu Y., Xie Y. et al. Soft-tissue sarcoma: modified grading method improves the accuracy of preoperative MRI in predicting patient outcomes. Eur Radiol 2025. DOI: 10.1007/s00330-025-11365-y

33. Guo J., Li Y., Guo H. et al. Parallel CNN-deep learning clinical- imaging signature for assessing pathologic grade and prognosis of soft tissue sarcoma patients. J Magn Reson Imaging 2025;61(2):807–19. DOI: 10.1002/jmri.29474

34. Guo X., Bian X., Li Y. et al. The intricate dance of tumor evolution: exploring immune escape, tumor migration, drug resistance, and treatment strategies. Biochim Biophys Acta Mol Basis Dis 2024;1870(4):167098. DOI: 10.1016/j.bbadis.2024.167098

35. Komdeur R., Plaat B.E.C., Hoekstra H.J. et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after chemotherapy. Cancer 2001;91(10):1940–8. DOI: 10.1002/1097-0142(20010515)91:10<1940::AID-CNCR1217>3.0.CO;2-3

36. Pierrevelcin M., Fuchs Q., Lhermitte B.M. et al. Focus on hypoxia- related pathways in pediatric osteosarcomas and their druggability. Cells 2020;9(9):1998. DOI: 10.3390/cells909199

37. Bigos K.J.A., Quiles C.G., Lunj S. et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front Oncol 2024;14:1331355. DOI: 10.3389/fonc.2024.1331355

38. Napolitano A., Huang P., Jones R.L. Novel therapeutics in soft tissue sarcoma. Cancers 2024;17(1):10. DOI: 10.3390/cancers17010010

39. Kim S.K., Kim J.H., Kim S.H. et al. PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. BMC Cancer 2021;21(1):336. DOI: 10.1186/s12885-021-08069-z

40. Panagi M., Pilavaki P., Constantinidou A. et al. Exploring the landscape of immunotherapy approaches in sarcomas. Front Oncol 2023;12:1069963. DOI: 10.3389/fonc.2022.1069963

41. Jones K.B. Synovial Sarcoma. In: Sarcoma oncology: a multidisciplinary approach. New York: Springer, 2019. Pp. 395–412.

42. Setsu N., Kohashi K., Fushimi F. et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer 2013;119(19):3504–13. DOI: 10.1002/cncr.28255

43. Qin W., Peng C., Yang X. et al. SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression. Cell Biol Toxicol 2024;41(1):8. DOI: 10.1007/s10565-024-09952-8

44. Ramteke P., Deb A., Shepal V., Bhat M.K. Hyperglycemia associated metabolic and molecular alterations in cancer risk, progression, treatment, and mortality. Cancers 2019;11(9):1402. DOI: 10.3390/cancers1109140

45. Mao X., Wu S., Huang D., Li C. Complications and comorbidities associated with antineoplastic chemotherapy: rethinking drug design and delivery for anticancer therapy. Acta Pharm Sin B 2024;14(7):2901–26. DOI: 10.1016/j.apsb.2024.03.006